Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients

Therapeutic Drug Monitoring

Volumn 23, Issue 5, 2001, Pages 514-519

  Filler, Guido ^a,c   Lepage, Nathalie ^a   Delisle, Brenda ^a   Mai, Ingrid ^b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Adolescents; Children; Cyclosporine; Mycophenolate mofetil area under the curve; Renal transplantation; Therapeutic drug monitoring

Indexed keywords

ACICLOVIR; AMLODIPINE; CALCINEURIN; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; CYCLOSPORIN; CYCLOSPORIN A; GANCICLOVIR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CHILDHOOD DISEASE; CONCENTRATION RESPONSE; CORRELATION FUNCTION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG GLUCURONIDATION; DRUG MONITORING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; HUMAN; INDIVIDUALITY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; SIDE EFFECT;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; CHILD; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; TREATMENT OUTCOME;

EID: 0034815929     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200110000-00003     Document Type: Article

References (31)

1. Factors influencing short-term and long-term pediatric renal transplant survival
2. Mycophenolate mofetil (RS 61443): Nothing new under the sun or an important break-through in the field of transplantation?
3. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil
4. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection
5. Mycophenolate mofetil (MMF) in pediatric (ped) renal transplantation (TX): Final report of the pediatric MMF study group (PMMFSG)
6. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients
7. Effect of adding Mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity
8. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpes-virus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo
9. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients
10. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation
11. Limited sampling strategy for mycophenolic acid area under the curve
12. Evaluation of the EMIT mycophenolic acid assay from Dade Behring
13. Therapeutic drug monitoring of mycophenolic acid: Comparison of HPLC and immunoassay reveals new MPA metabolites
14. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine
15. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients
16. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit
17. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression
18. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity
19. Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children
20. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients
21. Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite
22. Cyclosporine dosing and its relationship to outcome in pediatric renal transplantation
23. Which cyclosporine formulation?
24. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid
25. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid
26. Clinically significant drug interactions with new immunosuppressive agents
27. Clinical pharmacokinetics of mycophenolate mofetil
28. Mycophenolate mofetil for rescue therapy in acute renal transplant rejection in children should always be monitored by measurement of trough concentration
29. Dosing of MMF in combination with tacrolimus for steroid-resistant vascular rejection in pediatric renal allografts
30. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil
31. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation